Press Releases

Biomarkers market Growth at a CAGR of 16.2% from 2021 to 2030

Share This Article

The Biomarkers market is projected to reach US$  150.59 Bn by 2030. And registering a CAGR of around 16.2% over the forecast period 2021 – 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38602

Growth Factors

 The increasing prevalence of chronic diseases, advancements in the techniques used for the development of biomarker-based diagnostics, and the growing geriatric population are the key factors projected to boost the market growth over the forecast period. The rising number of COVID-19 cases across the globe and an increasing number of researches on the use of biomarkers for facilitating the detection & treatment of COVID-19 will also support market growth. by increasing collaborations & funds for R&D activities, rising consumer awareness, COVID-19 pandemic, and technological advancements in disease diagnosis. Research aids in the development of effective therapies for the treatment of various diseases, such as cancer, Cardiovascular Diseases (CVDs), immunological diseases, and neurological diseases.

Report Coverage

Report Scope Details
Market Size USD 150.59 billion by 2030
Growth Rate CAGR of 16.2% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Type, Application, Disease
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Epigenetics AG; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Siemens Healthineers AG; Qiagen

Report Highlights

 The safety biomarkers segment held the largest market share of more than 40% in 2020, driven by the high awareness about routine health checkups, lowered drug attrition rate, and a rise in population that is at high risk of developing various diseases, such as cancer, cardiovascular conditions, and kidney disorders. The validation biomarkers segment is expected to exhibit the second-fastest growth over the forecast period owing to the use of these biomarkers in the pharmaceutical sector to predict the therapeutic failure of pharmaceutical molecules with low therapeutic profiles and distinct genetic profiles.

The drug discovery & development segment dominated the biomarkers market in 2020 with a revenue share of more than 33.5% owing to extensive R&D initiatives for the development of targeted therapeutics, the ability to predict drug efficacy more easily, and a fast-track approval process. One such instance is the launch of targeted therapy for EGFR mutation in Non-small Cell Lung Cancer (NSCLC) patients by Halozyme, Inc.

The diagnostics segment is estimated to register the fastest CAGR over the forecast period owing to advantages in early-stage detection of disease, this creates an opportunity for the diagnostic segment to propel early diagnosis and improve the rate of diagnosis.

The cancer segment held the largest market share of more than 37% in 2020, driven by a rise in demand for rapid and accurate diagnostic tools, an increase in global cancer burden, and an unmet need for more specific, personalized, therapeutic targets for cancer patients. Its use for early detection of cancer, estimate prognosis, and monitor response to the treatment is expected to drive the market.

North America accounted for the highest revenue share of more than 46% of the global market. The increasing disease burden, growing consumer awareness, proactive government actions, technological breakthroughs, and improvements in healthcare infrastructure can be attributed to this growth. For instance, in 2020, the Canadian Government-funded USD 79,000 research project for COVID-19 biomarkers.

Key Players

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Epigenetics AG
  • General Electric
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Qiagen

Market Segmentation

  • Type
    • Safety
    • Efficacy
    • Validation
  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Personalized Medicines
    • Others
  • Disease
    • Cancer
      • Safety
      • Efficacy
      • Validation
    • Cardiovascular Diseases
      • Safety
      • Efficacy
      • Validation
    • Neurological Diseases
      • Safety
      • Efficacy
      • Validation
    • Immunological Diseases
      • Safety
      • Efficacy
      • Validation
    • Others
      • Safety
      • Efficacy
      • Validation
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Spain
      • France
      • Italy
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38602

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Biomarkers Market, By Type

7.1.  Biomarkers Market, by Type, 2021-2030

7.1.1.    Safety

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Efficacy

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Validation

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Biomarkers Market, By Application

8.1.  Biomarkers Market, by Application, 2021-2030

8.1.1.    Diagnostics

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Drug Discovery & Development

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Personalized Medicines

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Others

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Biomarkers Market, By Disease

9.1.  Biomarkers Market, by Disease, 2021-2030

9.1.1.    Cancer

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Cardiovascular Diseases

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Neurological Diseases

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Immunological Diseases

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Biomarkers Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Type (2017-2030)

10.1.2.  Market Revenue and Forecast, by Application (2017-2030)

10.1.3.  Market Revenue and Forecast, by Disease (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Type (2017-2030)

10.2.2.  Market Revenue and Forecast, by Application (2017-2030)

10.2.3.  Market Revenue and Forecast, by Disease (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Type (2017-2030)

10.3.2.  Market Revenue and Forecast, by Application (2017-2030)

10.3.3.  Market Revenue and Forecast, by Disease (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Type (2017-2030)

10.4.2.  Market Revenue and Forecast, by Application (2017-2030)

10.4.3.  Market Revenue and Forecast, by Disease (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Type (2017-2030)

10.5.2.  Market Revenue and Forecast, by Application (2017-2030)

10.5.3.  Market Revenue and Forecast, by Disease (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Disease (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Disease (2017-2030)

Chapter 11.  Company Profiles

11.1.              F. Hoffmann-La Roche Ltd.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Abbott Laboratories

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Epigenetics AG

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              General Electric

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Johnson & Johnson Services, Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Thermo Fisher Scientific, Inc.

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Bio-Rad Laboratories, Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Siemens Healthineers AG

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Qiagen

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38602

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Related Articles

Back to top button